Can Gallium-68 Prostate-specific Membrane Antigen Ligand be a Potential Radiotracer for Renal Cortical Positron Emission Tomography Imaging?

Ismet Sarikaya, Abdelhamid H. Elgazzar, Mahmoud A. Alfeeli, Ali Sarikaya

Department of Nuclear Medicine, Faculty of Medicine, Kuwait University, Safat 13110, 1Department of Nuclear Medicine, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait, 2Department of Nuclear Medicine, Faculty of Medicine, Trakya University, Edirne, Turkey

Abstract

Gallium-68 prostate-specific membrane antigen (Ga-68 PSMA) ligand (HBED-CC) is a new promising positron emission tomography (PET) tracer for prostate cancer. Intense renal parenchymal uptake is a physiologic finding on Ga-68 PSMA ligand PET images. Evaluation of kidneys in low intensity demonstrates excellent distribution of this radiotracer in renal parenchyma with excellent image quality and resolution. In this article, we present the Ga-68 PSMA ligand PET renal images of four patients with prostate cancer. In two patients, there is normal distribution of radiotracer, and in other two, there are renal cysts causing parenchymal defects.

Keywords: Gallium-68 prostate-specific membrane antigen ligand, kidney, positron emission tomography, renal cortex, renal parenchyma

Introduction

Renal cortical scintigraphy with technetium-99 m dimercapto succinic acid (Tc-99 m DMSA) has been widely used for decades to assess renal parenchyma. It is mainly utilized to detect acute pyelonephritis or scarring from chronic pyelonephritis, for quantitative assessment of relative functioning renal parenchyma/split function, detection of ectopic kidney, and evaluation of renal abnormalities.\(^1\)\(^{-3}\) In routine studies with Tc-99 m DMSA, planar images in multiple projections are usually obtained. Single-photon emission computed tomography (SPECT) imaging is optional. SPECT/computed tomography (CT) image is not preferred in children due to additional radiation dose from CT. Although it is a sensitive study in detecting scarring due to recurrent urinary tract infections, long waiting time for imaging after radiotracer injection which is approximately 2–3 h and relatively long image acquisition time of 30–60 min are not well tolerated by children.

In recent years, gallium-68 prostate-specific membrane antigen (Ga-68 PSMA) ligand positron emission tomography (PET) imaging has gained high attention for accurate staging of primary prostate cancer and restaging after biochemical recurrence.\(^4\)\(^{-6}\) Because we incidentally recognized excellent uptake of this tracer in the renal parenchyma with high-resolution images, we decided to present renal parenchymal PET images of Ga-68 PSMA ligand in our four patients in this article.

Address for correspondence:
Dr. Ismet Sarikaya, Department of Nuclear Medicine, Faculty of Medicine, Kuwait University, PO Box 24923, Safat 13110, Kuwait.
E-mail: isarikaya99@yahoo.com

Access this article online
Quick Response Code:
Website:
www.wjnm.org
DOI:
10.4103/wjnm.WJNM_35_17

How to cite this article: Sarikaya I, Elgazzar AH, Alfeeli MA, Sarikaya A. Can gallium-68 prostate-specific membrane antigen ligand be a potential radiotracer for renal cortical positron emission tomography imaging?: World J Nucl Med 2018;17:126-9.
Materials and Methods

Ga-68 PSMA ligand PET/CT images were obtained in four patients with prostate cancer to evaluate the extent of disease and diagnose recurrence. Radiolabeling was carried out at another institute (Kuwait Cancer Control Center). Images were obtained at Philips Time of Flight PET/CT camera. PET images were obtained 60 min following intravenous injection of 222 MBq (6 mCi) Ga-68 PSMA ligand. Before PET image acquisition, a low-dose CT was obtained for attenuation correction and anatomic localization purposes. PET acquisition was 3 min/bed from skull base to mid thighs. PET images were corrected for attenuation on the basis of the CT data and reconstructed using a standard iterative algorithm and reformatted into transaxial, coronal, and sagittal views. Maximum intensity projection images were also generated.

Due to intense uptake in the kidneys, PET images were reviewed in low intensity to better evaluate renal parenchymal uptake. Both attenuation corrected (AC) and uncorrected (non-AC) PET images as well as PET/CT fusion images were evaluated visually.

Results

Three patients were 66-year-old, and all had recently diagnosed prostate cancer (patients 1, 3, and 4). One patient had a history of prostate cancer with rising prostate-specific antigen value of 10 ng/ml (patient 2).

Figure 1 shows normal distribution of Ga-68 PSMA ligand (patient 4). Figure 2 shows normal renal parenchymal uptake of Ga-68 PSMA ligand (patient 1). Figure 3 shows normal renal parenchymal uptake of Ga-68 PSMA ligand with some mild pelvic excreted activity (patient 2).

Figure 4 shows focal renal parenchymal defect in the upper pole of the right kidney due to cyst (patient 3). Figure 5 demonstrates multiple renal parenchymal defects on PET corresponding to the multiple cysts seen on CT images (patient 4).

Discussion

PSMA is a Type II transmembrane protein with enzymatic activity which is mainly found in prostate tissue and is overexpressed in prostate cancer. It is also expressed in some other extraprostatic normal tissues including kidneys and malignancies. In an immunohistochemical analysis, detectable PSMA levels were identified in a subset of proximal renal tubules as well as some other tissues.

As clearly seen in our images of adult/elder patients, renal parenchymal uptake, image quality, and resolution with Ga-68 PSMA ligand PET appear to be excellent and better than Tc-99 m DMSA scintigraphy including planar, SPECT, and SPECT/CT. The majority of the excreted activity is already in the bladder at 60 min after radiotracer injection with no or mild pelvicalyceal activity to obscure parenchyma. For mild renal pelvic activity, images may be obtained with more delay at 90 min.

Effective and kidney radiation doses with Ga-68 PSMA ligand appear to be comparable or may be even less than Tc-99 m DMSA scintigraphy for per 37 MBq (1 mCi) of each radiotracer although this could be further studied. Ga-68 has also shorter half-life (68 min) than Tc-99 m (6 h).

Given high renal image quality in non-AC images, CT AC may not be necessary. This is particularly important for children to further reduce radiation dose. If there is need for CT, mainly in adults, it should include only renal region with 1 or 2 bed positions and abdominal and pelvic region if there is question for ectopic kidneys. Image acquisition time and waiting period after radiotracer injection are also significantly less with Ga-68 PSMA ligand PET imaging than with Tc-99 m DMSA.
Sarikaya, et al.: Ga-68 PSMA ligand for renal imaging

World Journal of Nuclear Medicine/Volume 17/Issue 2/April-June 2018

scintigraphy, approximately 5–6 min and 60–90 min versus 30–60 min and 2–3 h.

Main limitation of Ga-68 PSMA ligand PET imaging is its high cost as it requires PET camera, Ga-68 generator, and radiolabeling synthesis unit.

Ga-68 PSMA renal parenchymal images in our older age patients appear to be excellent, and we are expecting high quality maybe even better renal images in pediatric as well as young and middle-aged people although this should be further studied.

**Conclusion**

In hospitals with Ga-68 PSMA ligand availability, this tracer may substitute or be an alternative to Tc-99 m DMSA after careful radiation dosimetry and further renal imaging studies with this PET tracer, particularly in children.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Enlander D, Weber PM, dos Remedios LV. Renal cortical imaging in 35 patients: Superior quality with 99mTc-DMSA. J Nucl Med 1974;15:743-9.

2. Verber IG, Strudley MR, Meller ST. 99mTc dimercaptosuccinic acid (DMSA) scan as first investigation of urinary tract infection. Arch Dis Child 1988;63:1320-5.

3. Brenner M, Bonta D, Eslamy H, Ziessman HA. Comparison of 99mTc-DMSA dual-head SPECT versus high-resolution parallel-hole planar imaging for the detection of renal cortical defects. AJR Am J Roentgenol 2009;193:333-7.

4. Sterzing F, Kratochvil C, Fiedler H, Katayama S, Hahl G, Kopka K, et al. [68]Ga-PSMA-11 PET/CT: A new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging 2016;43:34-41.

5. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Leitz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the [68]Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:197-209.
6. Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, et al. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 2015;36:582-7.

7. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.

8. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr., Wang CY, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006;30:828-36.

9. Mandell GA, Eggli DF, Gilday DL, Heyman S, Leonard JC, Miller JH, et al. Procedure guideline for renal cortical scintigraphy in children. Society of Nuclear Medicine. J Nucl Med 1997;38:1644-6.

10. Afshar-Oromieh A, Hetzheim H, Köhler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68) Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging 2016;43:1611-20.